SR ONE CAPITAL MANAGEMENT, LP

CIK 0001910264 · Q2 2026

13F Equity AUM

$1.0B

+13.5% QoQ

Positions

+1 QoQ

AUM Rank

#3,320

Top 26%

Skill Alpha (FF)

+2.6%/yr^ns

No Clear Edge

Rank #1,155 · Top 14%

vs S&P -0.0%/yr (unadj.)

Quarters Tracked

~4 years

Portfolio Concentration

Top 5: 71.0%Top 10: 95.1%Top 20: 100.0%

Veradermics, Inc.28.4%

ZBIO12.3%

CRSP10.7%

Avalyn Pharma, Inc10.5%

DSGN9.1%

Odyssey Therapeutics, Inc.6.8%

ALMS5.3%

ORIC4.8%

MLYS4.1%

SPRY3.1%

Others (5)4.9%

HHI (Herfindahl-Hirschman Index) measures portfolio concentration. Low (<1500) = diversified, Moderate (1500-2500), High (>2500) = concentrated bets.

Sector Allocation

Healthcare50.9%

Unclassified49.1%

Portfolio weight by GICS sector based on latest 13F filing. Sectors below 2% are grouped as “Other.”

Position Sizing

Positions: 15Median: 4.81%Avg: 6.67%

0–0.5%

2(0.6%)

0.5–1%

2(1.8%)

1–3%

1(2.6%)

3–5%

3(12.0%)

5%+

7(83.1%)

Count of positions per weight bucket — (%) = combined portfolio weight

Loading summary cards...

Portfolio Overlap

Shared: 0Unique: 15vs 20 funds

0%Low

Fund positions

Consensus CUSIPs

Jaccard similarity of this fund’s portfolio vs the consensus of top 20 funds by AUM. Low (<15%) = contrarian, Moderate (15-40%), High (>40%) = follows the crowd.

Loading overlap analysis...

Position Changes This Quarter

New3Increased1Decreased0Exited2

New Positions

Avalyn Pharma, Inc10.5%

+3.3M

Odyssey Therapeutics…6.8%

+3.8M

Mobia Medical, Inc2.6%

+2.0M

Increased

ORIC4.8%

+100K(+2%)

Exited

ACLX

-2,346,630

ORKA

-430,330

Quarter-over-quarter changes compared to prior 13F filing. New = first appearance; Exited = no longer held.

Loading position changes...

Holdings

Loading holdings...